Medicare releases two new codes for combination bamlanivimab and etesevimab — the third FDA-approved COVID-19 antibody therapy. Our arsenal of treatment options for COVID-19 expands once again. On Feb. 18, the Centers for Medicare & Medicaid Services (CMS) released two new HCPCS Level II codes for Eli Lilly’s antibody cocktail. This comes after the U.S. […]
The post Reporting Eli Lilly’s Antibody Combo Therapy appeared first on AAPC Knowledge Center.